Roots and early history , the beginning of the
Merck Group Merck & Co. traces its origins to its former German parent company the
Merck Group, which was established by the
Merck family in 1668 when
Friedrich Jacob Merck purchased a pharmacy in
Darmstadt. In 1827, Merck Group evolved from a pharmacy to a drug manufacturer company with the commercial manufacture of
morphine. Merck perfected the chemical process of deriving morphine from
opium and later introduced
cocaine, used to treat sinus problems and to add to beverages to boost energy levels. In 1887 a German-born, long-time Merck employee, Theodore Weicker, went to the United States to represent Merck Group. In 1891, with $200,000 received from E. Merck, Weicker started Merck & Co., with headquarters in lower Manhattan. That year George Merck, the 23-year-old son of the then head of E. Merck (and grandson of the founder) joined Weicker in New York. The government seized 80 percent of the shares owned by the German parent company and sold it. In 1919, George F. Merck (head of the American branch of the Merck family), in partnership with
Goldman Sachs and
Lehman Brothers, bought the company back at a U.S. government auction for $3.5 million, but Merck & Co. remained a separate company from its former German parent. Merck & Co. holds the trademark rights to the "Merck" name in the United States and Canada, while its former parent company retains the rights in the rest of the world; the right to use the Merck name was the subject of litigation between the two companies in 2016. In 1929,
H. K. Mulford Company merged with Sharp and Dohme, Inc. and brought vaccine technology, including immunization of cavalry horses in World War I and delivery of a diphtheria antitoxin to Merck & Co. In 1943,
streptomycin was discovered during a Merck-funded research program in
Selman Waksman's laboratory at
Rutgers University. It became the first effective treatment for
tuberculosis. At the time of its discovery,
sanatoriums for the isolation of tuberculosis-infected people were a ubiquitous feature of cities in developed countries, with 50% dying within 5 years of admission. Although Merck's agreement with Rutgers gave it exclusive rights to streptomycin, at Waksman's request the company renegotiated the agreement, returning the rights to the university in exchange for a royalty. The university then set up non-exclusive licenses with seven companies to ensure a reliable supply of the antibiotic.
1950–2000 In the 1950s,
thiazide diuretics were developed by Merck scientists Karl H. Beyer, James M. Sprague, John E. Baer, and Frederick C. Novello and led to the marketing of the first drug of this class,
chlorothiazide, under the trade name Diuril in 1958. The research leading to the discovery of chlorothiazide, leading to "the saving of untold thousands of lives and the alleviation of the suffering of millions of victims of hypertension" was recognized by a special Public Health Award from the Lasker Foundation in 1975. In 1953, Merck & Co. merged with Philadelphia-based Sharp & Dohme, Inc., becoming the largest U.S. drugmaker. Sharp and Dohme had acquired
H. K. Mulford Company in 1929, adding
smallpox vaccines to its portfolio. The combined company kept the trade name Merck in the United States and Canada, and as Merck Sharp & Dohme (MSD) outside this two countries.
Maurice Hilleman, a scientist at Merck, developed the first
mumps vaccine in 1967, the first
rubella vaccine in 1969, and the first trivalent measles, mumps, rubella (
MMR vaccine) in 1971. The incidence of rubella-associated birth defects fell from up to 10,000 per year in the U.S. to zero in the aftermath of the rubella vaccine's development. Hilleman also developed the first
Hepatitis B vaccine and the first
varicella vaccine, for chickenpox. The company was incorporated in New Jersey in 1970.
John J. Horan became CEO and Chairman in 1976, serving until 1985. Under his leadership, the company's investment in R&D grew threefold, and Merck became the largest pharmaceutical company in the world. In 1979, Merck scientists developed
lovastatin (
Mevacor), the first drug of the
statin class. Merck scientist
William C. Campbell and
Satoshi Ōmura developed
ivermectin for
veterinary use in 1981, and later put it to human use against
onchocerciasis in 1987–1988 with the name Mectizan; today the compound is also used against
lymphatic filariasis,
scabies and other parasitic infections. In 1982, the company formed a
joint venture, KBI Inc., with
AstraZeneca. During the late 1980s and 1990s, the company also established joint ventures with
DuPont to access research and development expertise, and with
Johnson & Johnson to sell over-the-counter consumer medications. In 1985, Merck received approval for
imipenem, the first member of the
carbapenem class of antibiotics. Antibiotics of the carbapenem class play an important role in treatment guidelines for certain hospital-acquired and multi-drug resistant infections.
P. Roy Vagelos became CEO and Chairman that year, succeeding Horan. Vagelos served until reaching the company's mandatory retirement age in 1994, succeeded by
Raymond Gilmartin. In 1991, Merck's Kelco subsidiary was responsible for
volatile organic compound (VOC) emission pollution in the San Diego area. In 1996 Merck paid $1.8 million for polluting the air. New machines were installed to reduce smog emissions by a year. In November 1993, Merck & Co. acquired Medco Containment Services for $6 billion. Merck & Co. spun Medco off ten years later. Merck's
supply chain reduction programme has been referred to as an example of successful change. Merck reduced its number of global suppliers from 40,000 to less than 10,000 during the period from 1992 to 1997.
2001–2019 In May 2002, The
Bill & Melinda Gates Foundation purchased stock in Merck. From 2002 through 2005, the Australian affiliate of Merck paid publishing house
Elsevier an undisclosed amount to produce eight issues of a medical journal, the
Australasian Journal of Bone and Joint Medicine. Although it gave the appearance of being an independent peer-reviewed journal, without any indication that Merck had paid for it, the journal actually reprinted articles that originally appeared in other publications and that were favorable to Merck. The misleading publication came to light in 2009 during a personal injury lawsuit filed over Vioxx; 9 of 29 articles in the journal's second issue referred positively to Vioxx. The CEO of Elsevier's Health Sciences Division, Michael Hansen, admitted that the practice was "unacceptable". In 2005, Gilmartin retired as CEO following Merck's voluntary worldwide withdrawal of
Vioxx. Gilmartin's tenure was criticized as abandoning Vagelos' commitment to
corporate social responsibility. Former president of manufacturing
Richard Clark was named CEO and company president. In November 2009, Merck & Co. completed a merger with
Schering-Plough in a US$41 billion deal. Although Merck & Co. was in reality acquiring Schering-Plough, the purchase was declared a "reverse merger", in which "Old" Merck & Co. was renamed Merck Sharp & Dohme, and Schering-Plough renamed as "Merck & Co., Inc. The maneuver was an attempt avoid a "change-of-control" in order to preserve Schering-Plough's rights to market
Remicade. A settlement with
Johnson & Johnson was reached in 2011, in which Merck agreed to pay $500 million. Merck Sharp & Dohme remains a subsidiary of the Merck & Co. parent. In October 2013, Merck announced it would cut 8,500 jobs in an attempt to cut $2.5 billion from its costs by 2015. Combined with 7,500 job cuts announced in 2011 and 2012, the layoffs amounted to 20% of its workforce. By 2014, research performed at Merck has led to U.S. FDA approval of 63
new molecular entities. In August 2014, Merck acquired Idenix Pharmaceuticals for $3.85 billion. In September 2014, the US Food and Drug Administration (FDA) approved
Pembrolizumab (MK-3475) as a breakthrough therapy for melanoma treatment. In clinical trials, pembrolizumab provided partial tumor regression in about one quarter of patients, many of whom have not seen further progression of their disease in over 6 months of follow-up. In December 2014, the company acquired Swiss biotechnology company OncoEthix for up to $375 million. Between 2010 and 2015, the company cut around 36,450 jobs. During that time, the company sold its consumer health business to
Bayer and narrowed the company's focus to immunology, vaccines, diabetes, emerging markets and medicines used in hospitals, like certain antibiotics. In July 2015, Merck and
Ablynx expanded their 18-month-old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for the Abylnx. The company also announced it would spend $95 million up front collaborating with cCAM Biotherapeutics and its early-stage treatment similar to Keytruda. Merck & Co. will bring in CM-24, an antibody designed to block the immune checkpoint
CEACAM1. In January 2016, Merck announced two new partnerships; the first with Quartet Medicine and its small molecule pain treatments, the second with Complix investigating intracellular cancer targets, with both collaborations potentially generating up to $595 million and $280 million respectively. Days later the company announced it would acquire IOmet Pharma, with IOmet becoming a wholly owned subsidiary of Merck & Co. The acquisition includes IOmets
indoleamine-2,3-dioxygenase 1 (IDO),
tryptophan 2,3-dioxygenase (TDO), and dual-acting inhibitors. In July 2016, the company acquired Afferent Pharmaceuticals, developer of a candidate used to block
P2RX3 receptors, for approximately $1 billion, plus up to $750 million in milestone payments. In 2017, Merck bought the
PARP inhibitor Lynparza from AstraZeneca. In April 2017, Merck Animal Health acquired Vallée S.A., a Brazilian animal health product manufacturer. In September 2017, the company announced it would acquire Rigontec, developer of a candidate to target the
retinoic acid-inducible gene I pathway, for $554 million. In October 2017, the company granted the inaugural Merck-AGITG Clinical Research Fellowship in Gastro-Intestinal (GI) Cancer to David Lau, a professional in Melbourne, Australia. In June 2018, Merck acquired
Viralytics, an Australian viral cancer drug company, for AUD$502 million. In 2018, Merck began the submission process for a Biologics License Application to the
Food and Drug Administration under the Breakthrough Therapy Designation for an investigational vaccine, called V920, to fight the Zaire strain of the
Ebola virus. In April 2019, the company acquired Immune Design for approximately $300 million, gaining access to its immunotherapy programs. It also acquired Antelliq Group for $2.4 billion, or $3.7 billion including debt. In May 2019, Merck announced it would acquire Peloton Therapeutics, developer of a HIF-2alpha inhibitor for
Von Hippel–Lindau disease-associated
renal cell carcinoma, for up to $2.2 billion. In June 2019, Merck announced it would acquire Tilos Therapeutics for up to $773 million. In November 2019, the company acquired Calporta, which focused on Parkinsons and Alzheimers treatments. In December 2019, Merck Animal Health acquired Vaki, an aquaculture company, from
Pentair.
2020–present In January 2020, Merck acquired ArQule, developer of
ARQ 531, an oral
Bruton's tyrosine kinase (BTK) inhibitor, for $2.7 billion. In March 2020, Merck was one of ten companies recognised at the inaugural Manufacturing Awards by
New Jersey Business magazine and the
New Jersey Business and Industry Association. In June 2020, Merck acquired Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases including
COVID-19 and
cancer. Also in June 2020, Merck Animal Health acquired Quantified Ag, a data and analytics company that monitors cattle body temperature and movement in order to detect illness early. In August 2020, Merck Animal Health acquired
IdentiGEN, engaged in DNA-based animal traceability. In September 2020, Merck acquired $1 billion of
Seattle Genetics common stock, and agreed to co-develop ladiratuzumab vedotin. In November 2020, Merck announced it would acquire VelosBio for $2.75 billion, developer of VLS-101, an
antibody-drug conjugate designed to target
Tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors. VLS-101 is currently Phase I and Phase II clinical trials. The company also announced it would acquire OncoImmune for $425 million and its phase 3 candidate, CD24Fc, used in the treatment of patients with severe and critical COVID-19. In February 2021, Merck Animal Health acquired PrognostiX Poultry. In April 2021, Merck acquired Pandion Therapeutics for $1.85 billion, expanding its offering in treating autoimmune diseases. In June 2021, the U.S. government agreed to spend $1.2 billion to purchase 1.7 million doses of
Molnupiravir, a Merck product, if it were to be approved by regulators to treat
COVID-19. In October 2021, the company said that the drug reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of
COVID-19 and that it would seek
Emergency Use Authorization for the drug. In July 2021, Robert M. Davis became CEO, succeeding Kenneth Frazier, who became executive chairman. In July 2021, Merck completed the
corporate spin-off of
Organon & Co. In September 2021, Merck announced it would acquire
Acceleron Pharma for $11.5 billion, gaining control over
Sotatercept, used in the treatment of
pulmonary hypertension, and
luspatercept-aamt. In September 2022, the company announced it would acquire
Vence, a livestock management company for an undisclosed sum, incorporating it within
Merck Animal Health. In December 2022, the company announced a licensing deal with Kelun-Biotech of China whereby it would expand its early cancer pipeline with a set of
antibody-drug conjugates; this follows an earlier agreement between the two companies to co-develop such drugs. In April 2023, Merck announced it would acquire Prometheus Biosciences Inc for $10.8 billion. In December 2023, Merck announced it had partnered with
Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for immunotherapies. The aim is to come up with tools that can pre-screen patients with four tumour types for the MSI-H biomarker, namely endometrial, gastric, small intestinal, and biliary cancers. In January 2024, the company announced it would acquire Harpoon Therapeutics for $680 million. With this purchase, Merck expands its portfolio of oncological drugs. The main positions are HPN328, an activator of
T-cells that is being researched to treat advanced cancer patients associated with
DLL3 expression (delta-like ligand 3), an inherent
small cell lung cancer (SCLC),
neuroendocrine tumors, and several other species. Merck's portfolio will also be complemented by T-cell attractions using the patented Harpoon Tri-specific design for T cell activation (TriTAC). According to engineering protein technology, tumor cells are destroyed by the patient's own immune cells, and the ProTriTAC platform works with the TriTAC platform to develop a therapeutic agent that attracts T-cells, but is inactive until it reaches the tumor. In April 2024, Merck completed the acquisition of Abceutics for $208 million. In July 2024, Merck completed the acquisition of EyeBio for $3 billion. In October 2024, Merck announced the acquisition of Modifi Biosciences for $1.3 billion. In January 2026, the
Wall Street Journal reported that Merck was in talks to acquire Revolution Medicines for ~$30 billion.
Acquisition history •
Merck & Co • Merck & Co • Merck & Co • H. K. Mulford Company • Sharp & Dohme, Inc • Charles E. Frosst Ltd • Medco Containment Services Inc • Schering‑Plough •
Schering-Plough • Schering Corporation • Plough, Inc • Organon International • Alydia Health • Intervet • Diosynth • Nobilon • Imperial Blue Corporation • Idenix Pharmaceuticals • Maven Corporation •
Cubist Pharmaceuticals •
Trius Therapeutics • Optimer Pharmaceuticals • OncoEthix • IOmet Pharma • Afferent Pharmaceuticals • Merck Animal Health • Vallée S.A. • Vaki • Quantified Ag • IdentiGEN • PrognostiX Poultry Ltd • Vence • Rigontec •
Viralytics • Antelliq Group • Cascade Merger Sub, Inc. • Immune Design Corp • Peloton Therapeutics • Tilos Therapeutics • Calporta • Argon Merger Sub, Inc. • ArQule, Inc. • Themis Bioscience • VelosBio • OncoImmune • Astros Merger Sub, Inc. •
Acceleron Pharma • Prometheus Biosciences • Caraway Therapeutics • Harpoon Therapeutics • Abceutics • EyeBio • Modifi Biosciences • Verona Pharma plc ==Products==